XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.3

Subsequent Events	9 Months Ended
	Sep. 30, 2025
Subsequent Events [Abstract]
Subsequent Events	Subsequent Event In November 2025, the Company reported that it had completed the rolling submission of its Biologic License Application, or BLA, to the U.S. Food and Drug Administration, or FDA, for review under the FDA’s accelerated approval program, with the goal of receiving file acceptance by the FDA by the end of 2025. The Company has requested a priority review from the FDA, which, if granted, is expected to be completed within six months following the 60-day filing period.

X

- References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration